Medical network - February 7, in recent years, the global anti peptic ulcer drugs market scale in more than $20 billion, is still the big market drug use.
About 10% believed the crowd in his life had peptic ulcer, in different countries and regions, the disease incidence is bigger difference. As for peptic ulcer disease due to learn and new mechanism research, and anti peptic ulcer drugs have been developed, drug varieties structure, great changes have taken place in different periods. Ranitidine H2 - receptor antagonist global sales of $3.8 billion in 1994, the global annual sales of about $200 million. Proton pump inhibitors esso beauty pull azole global sales of $5.2 billion in 2007, the global annual sales of about $3.7 billion.
The global field of vision
Proton pump inhibitors (87.2%)
, according to the European association for the study of medical market classification of peptic ulcer drugs can be divided into five types: 1. The proton pump inhibitor. 2. The H2 receptor antagonist; 3. Bismuth preparations; 4. Prostaglandin classes; 5. Others. According to statistics, in October 2015 to September 2016 in 12 months, the global anti peptic ulcer medicine preparations factory for $20.83 billion. Global popular drugs for peptic ulcer types of market share as shown in figure 1.
Proton pump inhibitors $18.164 billion global market, the biggest market share, at 87.2%. Globally so far has listed seven new active ingredient proton pump inhibitors:
1. Prilosec (Omeprazole) : astrazeneca's original, first in 1988 in Sweden, Switzerland, the Netherlands and Luxembourg, name of commodity: los cyc (Losec). Otherwise: Omeprazole + Pan Li ketone (Omeprazole + Domperidone), commodity name Nogacid - D, the main sales company for Cadila company. Omeprazole Sodium (+ Omeprazole Sodium), commodity name Omepraz/Sod, the main sales company for Valeant company.
2. LAN sola azole (Lansoprazole) : takeda companies created, for the first time in 1991 in France, called Takepron goods. Otherwise: Amoxicillin + LAN sola azole + Clarithromycin (Amoxicillin + Lansoprazole + Clarithromycin), the main sales company for Prasco pharmaceutical factory.
3. The panxi tora azole (Pantoprazole) : nai Ming company (belonging to the takeda group co., LTD.) to create, first on the market in Germany, Mexico, in 1994 named Pantozol goods. Otherwise: Amoxicillin + panxi tora azole + Clarithromycin (Amoxicillin + Pantoprazole + Clarithromycin), called Pantocid goods, mainly for sun pharmaceutical sales company.
4. Ray Bella azole (RABEPRAZOLE) : eisai the original company, for the first time in 1997 in Japan, called Pariet goods. Packing: in February 2014, the joint preparations rabeprazole azole, amoxicillin and clarithromycin, commodity name Rabecure, and ray Bella azole, amoxicillin and metronidazole, commodity name Rabefine, listed on the Japanese used for removal of Helicobacter pylori (Helicobacter pylori).
5. Esso beauty pull azole (Esomeprazole) : for optical isomer of omeprazole (S) - (omeprazole), astrazeneca's initiative, first on the market in Germany, the United Kingdom in 2000, commodity called Nexium. Otherwise, esso beauty pull azole strontium (esomeprazole strontium), esso beauty pull azole magnesium (esomeprazole magnesium). Naproxen + esso beauty pull azole strontium (naproxen + esomeprazole strontium) for rheumatoid arthritis; Naproxen + esso beauty pull azole (naproxen + esomeprazole) used in ankylosing spondylitis, osteoarthritis, rheumatoid arthritis, stomach ulcers.
6. Mr. Pula azole (Ilaprazole) : the original South Korea Il Yang company, licensed to be company, in 2008 the first in China, commodity called lian (Yilian).
7. The right orchid sola azole (Dexlansoprazole) : takeda company initiatives, the FDA approved in the United States for the first time in 2009, called Dexilant goods.
According to statistics, in October 2015 to September 2016 in 12 months, the global scale of H2 receptor antagonist market for $1.499 billion, accounting for 7.2% of peptic ulcer drugs market.
The Chinese market, Asia's largest scale
Anti peptic ulcer drugs in the four regional markets around the world, Africa/Asia/Australia market biggest, at $8.49 billion, according to the floating exchange rate, fixed exchange rates, year-on-year growth of 2%, 2% respectively (the same below), 1 of the Chinese market, and $2.72 billion, year-on-year growth of 1%, respectively, 1%; The Japanese market as the second, $2.51 billion, year-on-year growth of 3%, respectively, of 4%. Other regional market performance as shown in figure 2.
Esso beauty pull azole highest sales
In October 2015 to September 2016, according to the preparation factory sales amount, astrazeneca's proton pump inhibitors esso beauty pull azole (trade name: nexium) is the highest brand in the global sales of peptic ulcer drugs drugs, annual sales of $3.7 billion, the other leading brands are shown in table 1.
The domestic market
Domestic anti peptic ulcer drugs are divided into 4 categories: proton pump inhibitors, H2 receptor blockers, mucous ulcer, other anti peptic ulcer drugs. PDB statistics according to China's pharmaceutical industry information center, according to data from 2016 years ago, three quarters forecast, hospital of domestic city 2016 samples of peptic ulcer drugs purchase amount is 5.812 billion yuan, including proton pump inhibitors for absolute market share of 91.8%, 4.3% H2 receptor blockers, mucous ulcer (2.1%), other of peptic ulcer drugs accounted for 1.8%.
11 years from 2005 to 2016, the domestic sample hospitals of peptic ulcer drugs purchase amount compound annual growth rate of 18.8%. Purchase amount and year-on-year growth trend as shown in figure 3.
Sora azole highest sales
In 2016, about 50 samples of peptic ulcer drugs into the domestic hospital sales, sora varieties of for the highest sales. According to the forecast data from 2016 years ago, three quarters, 2016 sora azole drug amount is about 1.44 billion yuan. Ahead of the first 10 varieties of six varieties are proton pump inhibitors, and firmly before six. Domestic anti peptic ulcer drugs in 2016 Top 10 varieties and Top 10 enterprises are shown in table 2 and table 3 respectively.
The table 3 shows that CR8 = 59.3%, therefore, the domestic anti peptic ulcer drugs can be coarse divided into oligopolistic market structure CR8 acuity (40%), subdivided into low concentrated oligopolistic type (40% or less CR8 < 70%).
Looking forward to > > >
Innovation is few varieties listed
Many varieties of peptic ulcer drugs into mature varieties, there are quite a number of varieties is prescription drugs (OTC), the market is generic (generics) competition.
More than 20 years almost did not see a innovation of peptic ulcer drugs varieties listed, but in January 2015, it was launched in Japan in the oral competition potassium acid blockers (potassium - competitive acid pump blocker) walter Nora praise (vonoprazan, commodity name: Takecab), used to treat acid related diseases, including: gastroesophageal reflux disease and peptic ulcer. This product by takeda companies original research, and promotion and otsuka company in Japan.
Different from the mechanism of the proton pump inhibitors, walter Nora praise cell in the lining of the stomach gastric acid secretion in the last step, inhibit ion to H K, K - atpase (proton pump) the combination of the role, to inhibit gastric acid secretion. Walter Nora praise with annual sales of $2015 and $26.6 million, forecast sales is expected to reach $700 million in 2021. |
